Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye diseaseopen access
- Authors
- Mun, Yongseok; Kwon, Ji-Won; Oh, Joo Youn
- Issue Date
- Sep-2018
- Publisher
- BMC
- Keywords
- Diquafosol tetrasodium 3%; Dry eye disease; Short tear film break-up time-type dry eye
- Citation
- BMC OPHTHALMOLOGY, v.18, no.1, pp.1 - 6
- Indexed
- SCIE
SCOPUS
- Journal Title
- BMC OPHTHALMOLOGY
- Volume
- 18
- Number
- 1
- Start Page
- 1
- End Page
- 6
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/149430
- DOI
- 10.1186/s12886-018-0910-3
- ISSN
- 1471-2415
- Abstract
- Background
To investigate therapeutic effects of topical diquafosol tetrasodium 3% ophthalmic solution in patients with short tear film break-up time (TFBUT)-type dry eye (DE).
Methods
The prospective study was performed in 70 eyes of 70 patients with short TFBUT-type DE. Diagnosis of short TFBUT-type DE was made based on the presence of DE symptoms, TFBUT value ≤5 s, corneoconjunctival staining score ≤ 2 (on a scale of 0 to 4), and Schirmer I value > 5 mm. Patients with systemic immunologic disorders or ocular graft-versus-host disease were excluded. Before and after instillation of 3% diquafosol ophthalmic solution six times per day for 4 weeks, subjective DE symptoms, TFBUT, corneoconjunctival staining score, and Schirmer I value were examined and compared. Also, demographic factors were compared between patients who showed improvement in each DE parameter by treatment and those who did not.
Results
Four-week treatment with 3% diquafosol ophthalmic solution significantly improved DE symptoms (p < 0.0001), increased TFBUT (p < 0.0001), and reduced corneoconjunctival staining scores (p < 0.0001). Schirmer I values were not changed by treatment. The age of patients who showed improvement in subjective DE symptoms after treatment was significantly lower than that of patients who did not (53.4 ± 27.5 vs. 63.3 ± 13.9 years, p = 0.012). Ocular side effects developed in 3 patients (4.3%), including conjunctival chemosis (n = 1) and persistent stinging sensation (n = 2).
Conclusions
Diquafosol tetrasodium 3% ophthalmic solution is effective in improving subjective symptoms and tear film stability in short TFBUT-type DE patients.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 교육협력지원교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/149430)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.